Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 123

1.

Evaluating ZNF217 mRNA Expression Levels as a Predictor of Response to Endocrine Therapy in ER+ Breast Cancer.

Vendrell JA, Solassol J, Győrffy B, Vilquin P, Jarlier M, Donini CF, Gamba L, Maudelonde T, Rouanet P, Cohen PA.

Front Pharmacol. 2019 Jan 25;9:1581. doi: 10.3389/fphar.2018.01581. eCollection 2018.

2.

High-risk HPV detection and associated cervical lesions in a population of French menopausal women.

Tifaoui N, Maudelonde T, Combecal J, Vallo R, Doutre S, Didelot MN, Nagot N, Segondy M, Boulle N.

J Clin Virol. 2018 Nov;108:12-18. doi: 10.1016/j.jcv.2018.08.010. Epub 2018 Aug 31.

PMID:
30196012
3.

Improving Mutation Screening in Patients with Colorectal Cancer Predisposition Using Next-Generation Sequencing.

Rey JM, Ducros V, Pujol P, Wang Q, Buisine MP, Aissaoui H, Maudelonde T, Olschwang S.

J Mol Diagn. 2017 Jul;19(4):589-601. doi: 10.1016/j.jmoldx.2017.04.005. Epub 2017 May 11.

PMID:
28502729
4.

Molecular Portrait of Metastasis-Competent Circulating Tumor Cells in Colon Cancer Reveals the Crucial Role of Genes Regulating Energy Metabolism and DNA Repair.

Alix-Panabières C, Cayrefourcq L, Mazard T, Maudelonde T, Assenat E, Assou S.

Clin Chem. 2017 Mar;63(3):700-713. doi: 10.1373/clinchem.2016.263582. Epub 2016 Dec 22.

5.

Comparative Methods to Improve the Detection of BRAF V600 Mutations in Highly Pigmented Melanoma Specimens.

Frouin E, Maudelonde T, Senal R, Larrieux M, Costes V, Godreuil S, Vendrell JA, Solassol J.

PLoS One. 2016 Jul 28;11(7):e0158698. doi: 10.1371/journal.pone.0158698. eCollection 2016.

6.

Histone deacetylase 9 regulates breast cancer cell proliferation and the response to histone deacetylase inhibitors.

Lapierre M, Linares A, Dalvai M, Duraffourd C, Bonnet S, Boulahtouf A, Rodriguez C, Jalaguier S, Assou S, Orsetti B, Balaguer P, Maudelonde T, Blache P, Bystricky K, Boulle N, Cavaillès V.

Oncotarget. 2016 Apr 12;7(15):19693-708. doi: 10.18632/oncotarget.7564.

7.

Frequent expression of PD-L1 on circulating breast cancer cells.

Mazel M, Jacot W, Pantel K, Bartkowiak K, Topart D, Cayrefourcq L, Rossille D, Maudelonde T, Fest T, Alix-Panabières C.

Mol Oncol. 2015 Nov;9(9):1773-82. doi: 10.1016/j.molonc.2015.05.009. Epub 2015 Jun 9.

8.

[New therapeutical strategies in metastatic hormone-dependent breast cancer].

Vilquin P, Cohen P, Maudelonde T, Tredan O, Treilleux I, Bachelot T, Heudel PE.

Bull Cancer. 2015 Apr;102(4):367-80. doi: 10.1016/j.bulcan.2015.02.013. Epub 2015 Mar 21. Review. French.

9.

Establishment and characterization of a cell line from human circulating colon cancer cells.

Cayrefourcq L, Mazard T, Joosse S, Solassol J, Ramos J, Assenat E, Schumacher U, Costes V, Maudelonde T, Pantel K, Alix-Panabières C.

Cancer Res. 2015 Mar 1;75(5):892-901. doi: 10.1158/0008-5472.CAN-14-2613. Epub 2015 Jan 15.

10.

Prognostic relevance of viable circulating tumor cells detected by EPISPOT in metastatic breast cancer patients.

Ramirez JM, Fehm T, Orsini M, Cayrefourcq L, Maudelonde T, Pantel K, Alix-Panabières C.

Clin Chem. 2014 Jan;60(1):214-21. doi: 10.1373/clinchem.2013.215079. Epub 2013 Nov 19.

11.

Capture of viable circulating tumor cells in the liver of colorectal cancer patients.

Denève E, Riethdorf S, Ramos J, Nocca D, Coffy A, Daurès JP, Maudelonde T, Fabre JM, Pantel K, Alix-Panabières C.

Clin Chem. 2013 Sep;59(9):1384-92. doi: 10.1373/clinchem.2013.202846. Epub 2013 May 21.

12.

Identification and validation of new autoantibodies for the diagnosis of DCIS and node negative early-stage breast cancers.

Lacombe J, Mangé A, Jarlier M, Bascoul-Mollevi C, Rouanet P, Lamy PJ, Maudelonde T, Solassol J.

Int J Cancer. 2013 Mar 1;132(5):1105-13. doi: 10.1002/ijc.27766. Epub 2012 Aug 28.

13.

HDL proteome in hemodialysis patients: a quantitative nanoflow liquid chromatography-tandem mass spectrometry approach.

Mangé A, Goux A, Badiou S, Patrier L, Canaud B, Maudelonde T, Cristol JP, Solassol J.

PLoS One. 2012;7(3):e34107. doi: 10.1371/journal.pone.0034107. Epub 2012 Mar 21.

14.

1P19Q loss but not IDH1 mutations influences WHO grade II gliomas spontaneous growth.

Gozé C, Bezzina C, Gozé E, Rigau V, Maudelonde T, Bauchet L, Duffau H.

J Neurooncol. 2012 May;108(1):69-75. doi: 10.1007/s11060-012-0831-6. Epub 2012 Mar 6.

PMID:
22392125
15.

Serum autoantibody signature of ductal carcinoma in situ progression to invasive breast cancer.

Mangé A, Lacombe J, Bascoul-Mollevi C, Jarlier M, Lamy PJ, Rouanet P, Maudelonde T, Solassol J.

Clin Cancer Res. 2012 Apr 1;18(7):1992-2000. doi: 10.1158/1078-0432.CCR-11-2527. Epub 2012 Feb 9.

16.

KRAS genotyping in rectal adenocarcinoma specimens with low tumor cellularity after neoadjuvant treatment.

Boissière-Michot F, Lopez-Crapez E, Frugier H, Berthe ML, Ho-Pun-Cheung A, Assenat E, Maudelonde T, Lamy PJ, Bibeau F.

Mod Pathol. 2012 May;25(5):731-9. doi: 10.1038/modpathol.2011.210. Epub 2012 Jan 27.

17.

Circulating epithelial cells in patients with benign colon diseases.

Pantel K, Denève E, Nocca D, Coffy A, Vendrell JP, Maudelonde T, Riethdorf S, Alix-Panabières C.

Clin Chem. 2012 May;58(5):936-40. doi: 10.1373/clinchem.2011.175570. Epub 2011 Dec 28.

18.

[Autoantibodies against tumor-related antigens: new tools for early detection of lung cancer].

Solassol J, Harmand PO, Maudelonde T, Pujol JL.

Bull Cancer. 2011 Dec;98(12):1419-30. doi: 10.1684/bdc.2011.1499. Review. French.

19.

[Serum autoantibodies profiling and early-stage cancer detection].

Desmetz C, Lacombe J, Mange A, Maudelonde T, Solassol J.

Med Sci (Paris). 2011 Jun-Jul;27(6-7):633-8. doi: 10.1051/medsci/2011276016. Epub 2011 Jul 1. Review. French.

20.

KRAS mutation detection in paired frozen and Formalin-Fixed Paraffin-Embedded (FFPE) colorectal cancer tissues.

Solassol J, Ramos J, Crapez E, Saifi M, Mangé A, Vianès E, Lamy PJ, Costes V, Maudelonde T.

Int J Mol Sci. 2011;12(5):3191-204. doi: 10.3390/ijms12053191. Epub 2011 May 17.

21.

Autoantibody signatures: progress and perspectives for early cancer detection.

Desmetz C, Mange A, Maudelonde T, Solassol J.

J Cell Mol Med. 2011 Oct;15(10):2013-24. doi: 10.1111/j.1582-4934.2011.01355.x. Review.

22.

Serum proteomic profiling reveals potential biomarkers for cutaneous malignant melanoma.

Solassol J, Du-Thanh A, Maudelonde T, Guillot B.

Int J Biol Markers. 2011 Apr-Jun;26(2):82-7. doi: 10.5301/JBM.2011.8344. Review.

PMID:
21607923
23.

FKBP family proteins as promising new biomarkers for cancer.

Solassol J, Mange A, Maudelonde T.

Curr Opin Pharmacol. 2011 Aug;11(4):320-5. doi: 10.1016/j.coph.2011.03.012. Epub 2011 Apr 20. Review.

PMID:
21514221
24.

[Circulating prognosis markers in melanoma: proteomic profiling and clinical studies].

Solassol J, Guillot B, Maudelonde T.

Ann Biol Clin (Paris). 2011 Mar-Apr;69(2):151-7. doi: 10.1684/abc.2011.0523. Review. French.

25.

Clinical relevance of autoantibody detection in lung cancer.

Solassol J, Maudelonde T, Mange A, Pujol JL.

J Thorac Oncol. 2011 May;6(5):955-62. doi: 10.1097/JTO.0b013e318215a0a4. Review.

26.

Pemphigus vulgaris antigen mRNA quantification for the staging of sentinel lymph nodes in head and neck cancer.

Solassol J, Burcia V, Costes V, Lacombe J, Mange A, Barbotte E, de Verbizier D, Cartier C, Makeieff M, Crampette L, Boulle N, Maudelonde T, Guerrier B, Garrel R.

Br J Cancer. 2010 Jan 5;102(1):181-7. doi: 10.1038/sj.bjc.6605470. Epub 2009 Dec 8.

27.

Serum protein signature may improve detection of ductal carcinoma in situ of the breast.

Solassol J, Rouanet P, Lamy PJ, Allal C, Favre G, Maudelonde T, Mangé A.

Oncogene. 2010 Jan 28;29(4):550-60. doi: 10.1038/onc.2009.341. Epub 2009 Oct 26.

PMID:
19855429
28.

Identifying autoantibody signatures in cancer: a promising challenge.

Desmetz C, Maudelonde T, Mangé A, Solassol J.

Expert Rev Proteomics. 2009 Aug;6(4):377-86. doi: 10.1586/epr.09.56. Review.

PMID:
19681673
29.

Identification of a new panel of serum autoantibodies associated with the presence of in situ carcinoma of the breast in younger women.

Desmetz C, Bascoul-Mollevi C, Rochaix P, Lamy PJ, Kramar A, Rouanet P, Maudelonde T, Mangé A, Solassol J.

Clin Cancer Res. 2009 Jul 15;15(14):4733-41. doi: 10.1158/1078-0432.CCR-08-3307. Epub 2009 Jul 7.

30.

Regulation of activities of steroid hormone receptors by tibolone and its primary metabolites.

Escande A, Servant N, Rabenoelina F, Auzou G, Kloosterboer H, Cavaillès V, Balaguer P, Maudelonde T.

J Steroid Biochem Mol Biol. 2009 Aug;116(1-2):8-14. doi: 10.1016/j.jsbmb.2009.03.008. Epub 2009 Apr 2.

31.

Specific activity of class II histone deacetylases in human breast cancer cells.

Duong V, Bret C, Altucci L, Mai A, Duraffourd C, Loubersac J, Harmand PO, Bonnet S, Valente S, Maudelonde T, Cavailles V, Boulle N.

Mol Cancer Res. 2008 Dec;6(12):1908-19. doi: 10.1158/1541-7786.MCR-08-0299.

32.

Proteomic analysis of RCL2 paraffin-embedded tissues.

Bellet V, Boissière F, Bibeau F, Desmetz C, Berthe ML, Rochaix P, Maudelonde T, Mangè A, Solassol J.

J Cell Mol Med. 2008 Oct;12(5B):2027-36. doi: 10.1111/j.1582-4934.2008.00186.x.

33.

Lack of complete 1p19q deletion in a consecutive series of 12 WHO grade II gliomas involving the insula: a marker of worse prognosis?

Gozé C, Rigau V, Gibert L, Maudelonde T, Duffau H.

J Neurooncol. 2009 Jan;91(1):1-5. doi: 10.1007/s11060-008-9680-8. Epub 2008 Aug 23.

PMID:
18726074
34.

Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter?

Miller WR, Bartlett J, Brodie AM, Brueggemeier RW, di Salle E, Lønning PE, Llombart A, Maass N, Maudelonde T, Sasano H, Goss PE.

Oncologist. 2008 Aug;13(8):829-37. doi: 10.1634/theoncologist.2008-0055. Epub 2008 Aug 11. Review.

35.

Specific increase of human kallikrein 4 mRNA and protein levels in breast cancer stromal cells.

Mangé A, Desmetz C, Berthes ML, Maudelonde T, Solassol J.

Biochem Biophys Res Commun. 2008 Oct 10;375(1):107-12. doi: 10.1016/j.bbrc.2008.07.138. Epub 2008 Aug 5.

PMID:
18687310
36.

Proteomics-based identification of HSP60 as a tumor-associated antigen in early stage breast cancer and ductal carcinoma in situ.

Desmetz C, Bibeau F, Boissière F, Bellet V, Rouanet P, Maudelonde T, Mangé A, Solassol J.

J Proteome Res. 2008 Sep;7(9):3830-7. doi: 10.1021/pr800130d. Epub 2008 Aug 7.

PMID:
18683965
37.

Serum proteomic profiling of lung cancer in high-risk groups and determination of clinical outcomes.

Jacot W, Lhermitte L, Dossat N, Pujol JL, Molinari N, Daurès JP, Maudelonde T, Mangé A, Solassol J.

J Thorac Oncol. 2008 Aug;3(8):840-50. doi: 10.1097/JTO.0b013e31817e464a.

38.

Opposite effects of transforming growth factor-beta activation and rho-associated kinase inhibition on human trophoblast migration in a reconstituted placental-endometrial coculture system.

Fafet P, Rebouissou C, Maudelonde T, Vignais ML.

Endocrinology. 2008 Sep;149(9):4475-85. doi: 10.1210/en.2008-0253. Epub 2008 May 22.

PMID:
18499753
39.

Expression of estrogen receptors alpha and beta in early steps of human breast carcinogenesis.

Roger P, Esslimani-Sahla M, Delfour C, Lazennec G, Rochefort H, Maudelonde T.

Adv Exp Med Biol. 2008;617:139-48. doi: 10.1007/978-0-387-69080-3_13. Review. No abstract available.

PMID:
18497038
40.

Hormonal carcinogenesis V. Preface.

Li JJ, Li SA, Mohla S, Rochefort H, Maudelonde T.

Adv Exp Med Biol. 2008;617:ix-x. No abstract available.

PMID:
18497025
41.

Proteomic profile determination of autosomal aneuploidies by mass spectrometry on amniotic fluids.

Mange A, Desmetz C, Bellet V, Molinari N, Maudelonde T, Solassol J.

Proteome Sci. 2008 Jan 11;6:1. doi: 10.1186/1477-5956-6-1.

42.

Comparison of supervised classification methods for protein profiling in cancer diagnosis.

Dossat N, Mangé A, Solassol J, Jacot W, Lhermitte L, Maudelonde T, Daurès JP, Molinari N.

Cancer Inform. 2007 Jul 19;3:295-305.

43.

Peroxisome proliferator-activated receptor gamma regulates E-cadherin expression and inhibits growth and invasion of prostate cancer.

Annicotte JS, Iankova I, Miard S, Fritz V, Sarruf D, Abella A, Berthe ML, Noël D, Pillon A, Iborra F, Dubus P, Maudelonde T, Culine S, Fajas L.

Mol Cell Biol. 2006 Oct;26(20):7561-74.

44.

Clinical proteomics and mass spectrometry profiling for cancer detection.

Solassol J, Jacot W, Lhermitte L, Boulle N, Maudelonde T, Mangé A.

Expert Rev Proteomics. 2006 Jun;3(3):311-20. Review.

PMID:
16771703
45.

RCL2, a new fixative, preserves morphology and nucleic acid integrity in paraffin-embedded breast carcinoma and microdissected breast tumor cells.

Delfour C, Roger P, Bret C, Berthe ML, Rochaix P, Kalfa N, Raynaud P, Bibeau F, Maudelonde T, Boulle N.

J Mol Diagn. 2006 May;8(2):157-69.

46.

[Proteomic profiling: the potential of Seldi-Tof for the identification of new cancer biomarkers].

Solassol J, Marin P, Maudelonde T, Mangé A.

Bull Cancer. 2005 Sep;92(9):763-8. Review. French.

47.

[Clinical proteomics: towards early detection of cancers].

Solassol J, Boulle N, Maudelonde T, Mangé A.

Med Sci (Paris). 2005 Aug-Sep;21(8-9):722-9. Review. French.

48.

The nuclear receptor liver receptor homolog-1 is an estrogen receptor target gene.

Annicotte JS, Chavey C, Servant N, Teyssier J, Bardin A, Licznar A, Badia E, Pujol P, Vignon F, Maudelonde T, Lazennec G, Cavailles V, Fajas L.

Oncogene. 2005 Dec 8;24(55):8167-75.

49.

Detection of circulating prostate-specific antigen-secreting cells in prostate cancer patients.

Alix-Panabières C, Rebillard X, Brouillet JP, Barbotte E, Iborra F, Segui B, Maudelonde T, Jolivet-Reynaud C, Vendrell JP.

Clin Chem. 2005 Aug;51(8):1538-41. No abstract available.

50.

Characterization and enumeration of cells secreting tumor markers in the peripheral blood of breast cancer patients.

Alix-Panabières C, Brouillet JP, Fabbro M, Yssel H, Rousset T, Maudelonde T, Choquet-Kastylevsky G, Vendrell JP.

J Immunol Methods. 2005 Apr;299(1-2):177-88. Epub 2005 Apr 12.

PMID:
15914200

Supplemental Content

Loading ...
Support Center